[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598078":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":32,"studyPopulation":36,"armGroups":37,"interventions":32,"overallOfficials":32,"centralContacts":47,"locations":53,"responsibleParty":73,"collaborators":32,"id":77,"slug":32,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":32,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":32,"maxAge":32,"enrollmentInfo":84,"targetDuration":32,"studyType":87,"phases":32,"briefSummary":88,"conditions":89,"keywords":32,"overallStatus":56,"whyStopped":32,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Central South University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":32},[9,13],{"measure":10,"description":11,"timeFrame":12},"DFS","Disease-Free Survival","From enrollment to the end of surgery for 5 years",{"measure":14,"description":15,"timeFrame":12},"OS","Overall Survival",[17,20,23,26,29],{"measure":18,"description":19,"timeFrame":12},"Rate of T-stage reclassification","T-stage reclassification",{"measure":21,"description":22,"timeFrame":12},"AI-based extraction of radiologic characteristics of cystic airspace-associated lesions","Machine learning was employed to extract and analyze the radiologic characteristics of cystic airspace-associated lesions.",{"measure":24,"description":25,"timeFrame":12},"AI to extract and analyze pathological features","Machine learning was employed to extract and analyze pathological features",{"measure":27,"description":28,"timeFrame":12},"Oncogenic driver genetic alterations","Results of driver gene mutation testing",{"measure":30,"description":31,"timeFrame":12},"Receipt of postoperative adjuvant therapy","Postoperative adjuvant therapy was ascertained from medical records",null,{"allocation":32,"interventionModel":32,"interventionModelDescription":32,"primaryPurpose":32,"observationalModel":34,"timePerspective":35,"maskingInfo":32},"COHORT","RETROSPECTIVE","Patients with LCCA who underwent surgical treatment in the Second Xiangya Hospital of Central South University",[38,41,44],{"label":39,"type":32,"description":40,"interventionNames":32},"group 1","radiologic T stage based on the maximum tumor diameter including cystic components",{"label":42,"type":32,"description":43,"interventionNames":32},"group 2","radiologic T stage based on the diameter of the solid\u002Finvasive portion only",{"label":45,"type":32,"description":46,"interventionNames":32},"group 3","pathologic T stage derived from the resected specimen",[48],{"name":49,"role":50,"phone":51,"phoneExt":32,"email":52},"Chen Chen","CONTACT","+8673185295188","chenchen1981412@csu.edu.cn",[54],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"The Second Xiangya Hospital of Central South University","RECRUITING","Changsha","Hunan","410011","China","CN",{"type":63,"coordinates":64},"Point",[65,66],112.97087,28.19874,{"lat":66,"lon":65},[69],{"name":70,"role":50,"phone":71,"phoneExt":32,"email":72},"Ping Jiang","0731-85292476","xy2gcpjiang@163.com",{"type":74,"investigatorFullName":49,"investigatorTitle":75,"investigatorAffiliation":76,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Associate Professor","Second Xiangya Hospital of Central South University","100598078",false,"NCT07066813","Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces","T-Staging Strategies and Their Prognostic and Therapeutic Significance in Lung Cancer With Cystic Airspaces: A Retrospective Cohort Study","Inclusion Criteria:\n\n1. Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination;\n2. Patients who have undergone surgical lung resection;\n3. Patients with complete preoperative chest CT imaging data;\n4. Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor.\n\nExclusion Criteria:\n\n1. History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis \\[LAM\\], or Birt-Hogg-Dubé \\[BHD\\] syndrome);\n2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;\n3. Patients with concurrent other malignancies;\n4. Patients with missing or poor-quality preoperative chest CT imaging data.","ALL",{"count":85,"type":86},500,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are:\n\n* What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes?\n* How do imaging features of cystic lesions correlate with their pathological characteristics?\n* What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis?\n* Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?",[90],"Lung Cancer Associated With Cystic Airspaces","2026-03-16",{"date":93,"type":94},"2026-03-18","ACTUAL",{"date":96,"type":94},"2025-06-01",{"date":98,"type":86},"2026-07-01",{"name":5,"class":6},1]